Pulmonary veno-occlusive disease is a rare cause of pulmonary hypertension of unknown aetiology. Pulmonary veno-occlusive disease is usually an isolated condition but has been reported in association with autoimmune vasculitis' and may follow viral or toxoplasmal infection.2 We report a case of pulmonary veno-occlusive disease in association with Hodgkin' s disease, a combination not previously described, and consider what treatment could be used to lower the pulmonary arterial pressure.
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Case report
A 22 year old man, a gardener, who had previously been well, presented with a four month history of increasing dyspnoea, non-productive cough, retrosternal chest discomfort, and weight loss. On examination he had extensive acne vulgaris and bilateral axillary lymphadenopathy. The extremities were cool but no other abnormal physical signs were found. A biopsy specimen of a lymph node showed appearances of reactive hyperplasia. When reviewed four weeks later he was unable to walk more than about 45 metres on level ground because of breathlessness. He had sinus tachycardia, raised venous pressure, accentuation of the right ventricular impulse, a delayed and loud pulmonary second heart sound, and a third heart sound audible at the left sternal edge. No Prednisolone was withdrawn and treatment with hydrallazine, oxygen, azathioprine, and warfarin continued. Symptomatic improvement occurred over the next four weeks, with an increase in exercise tolerance to about 100 m on level ground The patient was discharged from hospital and for four months there was no clinical deterioration, although symptoms were variable from day to day. He died suddenly while away from home on holiday five months after starting treatment with hydrallazine and 12 months after the onset of symptoms. No necropsy was performed.
Discussion
Pulmonary veno-occlusive disease is a rare condition with a poor prognosis, most patients surviving less that two years from diagnosis.3 The diagnosis may be suspected when the clinical signs of pulmonary hypertension are accompanied by radiological signs of pulmonary oedema in the absence of structural heart disease4 but is usually made by histological examination of lung tissue obtained either at open lung biopsy or at necropsy. Treatment has been disappointing; corticosteroids have failed to produce improvement3 and vasodilators used briefly in one patient gave unconvincing results.5 The reported exception was a 46 year old woman with pulmonary veno-occlusive disease and autoimmune vasculitis who responded to azathioprine and was alive four years later.' In our patient hydrallazine produced a sustained fall in pulmonary arterial pressure that was enhanced by breathing 60% oxygen and we think that this was largely responsible for the observed clinical improvement, although prognosis was probably not affected. The association with Hodgkin's disease remains unexplained.
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